U.S. markets close in 4 hours 26 minutes
  • S&P 500

    3,894.74
    +83.59 (+2.19%)
     
  • Dow 30

    31,593.19
    +660.82 (+2.14%)
     
  • Nasdaq

    13,499.51
    +307.16 (+2.33%)
     
  • Russell 2000

    2,264.98
    +63.93 (+2.90%)
     
  • Crude Oil

    61.84
    +0.34 (+0.55%)
     
  • Gold

    1,736.70
    +7.90 (+0.46%)
     
  • Silver

    26.94
    +0.50 (+1.89%)
     
  • EUR/USD

    1.2054
    -0.0034 (-0.28%)
     
  • 10-Yr Bond

    1.4360
    -0.0240 (-1.64%)
     
  • GBP/USD

    1.3946
    +0.0024 (+0.17%)
     
  • USD/JPY

    106.6430
    +0.1410 (+0.13%)
     
  • BTC-USD

    49,187.30
    +5,338.34 (+12.17%)
     
  • CMC Crypto 200

    986.02
    +57.78 (+6.23%)
     
  • FTSE 100

    6,593.47
    +110.04 (+1.70%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

When Should You Buy HealthEquity, Inc. (NASDAQ:HQY)?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

HealthEquity, Inc. (NASDAQ:HQY), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Let’s take a look at HealthEquity’s outlook and value based on the most recent financial data to see if the opportunity still exists.

See our latest analysis for HealthEquity

What is HealthEquity worth?

Good news, investors! HealthEquity is still a bargain right now. According to my valuation, the intrinsic value for the stock is $74.49, but it is currently trading at US$54.30 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, HealthEquity’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from HealthEquity?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. HealthEquity's revenue growth are expected to be in the teens in the upcoming years, indicating a solid future ahead. Unless expenses grow at the same level, or higher, this top-line growth should lead to robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since HQY is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on HQY for a while, now might be the time to make a leap. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy HQY. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.

If you want to dive deeper into HealthEquity, you'd also look into what risks it is currently facing. Case in point: We've spotted 2 warning signs for HealthEquity you should be mindful of and 1 of these is a bit concerning.

If you are no longer interested in HealthEquity, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.